Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adult Patients With Schizophrenia

NCT04158687 is registered in ClinicalTrials.gov with Concert Pharmaceuticals as lead sponsor.

NCT NCT04158687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04158687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adult Patients With Schizophrenia
Lead sponsor
Concert Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 26, 2019
Completion date
December 22, 2020
Enrollment
326 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia